Spruce Biosciences, Inc. (SPRB) Stock Forecast
SPRB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.89 / 5 from 9 analysts
- Price target
- $148.00 average of analyst targets
- Upside to target
- +273.3% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-5.76
- 52-week range
- $38.98 – $148.16
SPRB analyst ratings
9 analystsNumber of analysts at each rating.
SPRB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SPRB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$5.51 | −$6.92 | −$4.24 | −$14.58 | +62.2% | 8 |
| Current fiscal year (2026) | −$25.32 | −$32.69 | −$16.26 | −$50.83 | +50.2% | 8 |
| Next fiscal year (2027) | $4.97 | −$19.26 | $38.23 | −$25.32 | +119.6% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SPRB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 9 |
| Next fiscal year (2027) | $78.7M | $0 | $200.0M | 0.0% | 9 |
SPRB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SPRB revenue: reported and forecast
SPRB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$5.96 | −$5.72 | −$5.69 | −$5.51 | −$5.51 | −7.6% | 2 up · 5 down |
| Current fiscal year (2026) | −$26.30 | −$25.32 | −$26.61 | −$25.32 | −$25.32 | −3.7% | 1 up · 5 down |
| Next fiscal year (2027) | $9.79 | $11.82 | $8.17 | $4.97 | $4.97 | −49.2% | 4 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SPRB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SPRB beat in 6 of 12.
What analysts expect from SPRB
9 analysts cover Spruce Biosciences; their consensus rating is strong buy (4.89 on a 1–5 scale, where 5 is a strong buy). The average price target is $148.00, 273.3% above the latest close of $39.65. Analysts expect earnings of −$25.32 per share for 2026, +50.2% from a year earlier. For 2027 the average estimate is $4.97 per share on revenue of $78.7 million. Spruce Biosciences beat the EPS estimate in 6 of the last 12 quarters.
Related: SPRB income statement, SPRB key metrics, SPRB chart. See the SPRB stock overview for the latest quote and news.
SPRB forecast FAQ
What is Spruce Biosciences's price target?
The average analyst price target for Spruce Biosciences is $148.00, 273.3% above the latest close of $39.65.
Is Spruce Biosciences a buy, hold or sell?
Of 9 analysts covering Spruce Biosciences, 8 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Spruce Biosciences's EPS forecast?
Analysts forecast −$25.32 per share for 2026 (range −$32.69 to −$16.26); for 2027 the estimate is $4.97.
When does Spruce Biosciences report earnings?
Spruce Biosciences is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-5.76.
Does Spruce Biosciences usually beat earnings estimates?
Spruce Biosciences reported EPS at or above the analyst estimate in 6 of the last 12 quarters.